Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.

[1]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[2]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[3]  J. Mohler.  The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  Antoinette M Stroup,et al.  Prostate cancer early detection , 2010 .

[5]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[6]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[7]  A. Italiano,et al.  Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. , 2009, European urology.

[8]  A. Bono,et al.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. , 2009, European urology.

[9]  B. Tombal.  Intermittent androgen deprivation therapy: conventional wisdom versus evidence. , 2009, European urology.

[10]  M. Kattan,et al.  Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer , 2009, Cancer.

[11]  L. Holmberg,et al.  Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. , 2009, European urology.

[12]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.

[13]  J. Thüroff,et al.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. , 2008, European urology.

[14]  I. Tannock,et al.  Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Moul,et al.  Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. , 2008, Urology.

[16]  K. Chi,et al.  Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer , 2008, Current opinion in supportive and palliative care.

[17]  I. Bourdel-Marchasson,et al.  Undernutrition in elderly patients with cancer: target for diagnosis and intervention. , 2008, Critical reviews in oncology/hematology.

[18]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[19]  J. Pierga,et al.  Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[20]  F. Saad,et al.  Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. , 2008, European urology.

[21]  S. Basaria,et al.  Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  A. Partin,et al.  Progression after radical prostatectomy for men in their thirties compared to older men , 2008, BJU international.

[23]  L. Collette,et al.  Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). , 2008, European urology.

[24]  M. Aapro,et al.  September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. , 2008, The oncologist.

[25]  F. Montorsi,et al.  The effect of surgical volume, age and comorbidities on 30‐day mortality after radical prostatectomy: a population‐based analysis of 9208 consecutive cases , 2008, BJU international.

[26]  J. Droz,et al.  Management of metastatic prostate cancer: the crucial role of geriatric assessment , 2008, BJU international.

[27]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[28]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[29]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Fosså,et al.  Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. , 2007, European urology.

[31]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[32]  H. Wildiers,et al.  Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  T. Wilt,et al.  Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness , 2007, BJU international.

[34]  A. D'Amico,et al.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[36]  M. Barry.  Re: Survival Associated with Treatment vs Observation of Localized Prostate Cancer in Elderly Men , 2007 .

[37]  P. Kantoff,et al.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Ell,et al.  Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone pain , 2007, Cancer.

[39]  K. Miller,et al.  Chemotherapy for older patients with prostate cancer , 2007, BJU international.

[40]  K. Armstrong,et al.  Survival associated with treatment vs observation of localized prostate cancer in elderly men. , 2006, JAMA.

[41]  B. Palumbo,et al.  Platelet function after single [153Sm]EDTMP therapy in prostate cancer. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[42]  A. D'Amico,et al.  Patient and treatment factors associated with complications after prostate brachytherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  G. Aus,et al.  Current status of HIFU and cryotherapy in prostate cancer--a review. , 2006, European urology.

[45]  G. Batist,et al.  O9 Usefulness of frailty markers in the assessment of the health and functional status in older cancer patient referred for chemotherapy: a pilot study , 2006 .

[46]  Ruth Etzioni,et al.  Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[47]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  K. Schulman,et al.  Prostate specific antigen testing in men older than 75 years in the United States. , 2006, The Journal of urology.

[49]  M. Theodoulou,et al.  A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy , 2006, Journal of the American Geriatrics Society.

[50]  G. Lyman,et al.  Muscle weakness is a significant problem in older patients receiving chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Coebergh,et al.  Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study , 2006, Prostate Cancer and Prostatic Diseases.

[52]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[53]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Stanford,et al.  Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. , 2006, The American journal of medicine.

[55]  L. Collette,et al.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Harvey.  Cryosurgery for Prostate Cancer , 2006, Journal of perioperative practice.

[57]  J. Goodwin,et al.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. , 2006, Archives of internal medicine.

[58]  Karla Lindquist,et al.  Development and validation of a prognostic index for 4-year mortality in older adults. , 2006, JAMA.

[59]  S. Lichtman.  Therapy Insight: therapeutic challenges in the treatment of elderly cancer patients , 2006, Nature Clinical Practice Oncology.

[60]  M. Wirth,et al.  Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer , 2006, BJU international.

[61]  J. Concato,et al.  The effectiveness of screening for prostate cancer: a nested case-control study. , 2006, Archives of internal medicine.

[62]  M. Extermann.  Geriatric Assessment with Focus on Instrument Selectivity for Outcomes , 2005, Cancer journal.

[63]  B. Weber,et al.  Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  G. Naglie,et al.  30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. , 2005, Journal of the National Cancer Institute.

[65]  A. D'Amico,et al.  Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  H. Cohen,et al.  Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). , 2005, Critical reviews in oncology/hematology.

[67]  P. Walsh.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The Journal of urology.

[68]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[69]  H. Geinitz,et al.  3D conformal radiation therapy for prostate cancer in elderly patients. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[70]  Srinivasan Vijayakumar,et al.  Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. , 2005, Urology.

[71]  H. Cohen,et al.  Geriatric evaluation and management units in the care of the frail elderly cancer patient. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[72]  N. Khandelwal,et al.  Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy , 2005, Cancer.

[73]  L. Siu,et al.  Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Goodwin,et al.  Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.

[75]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[76]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[77]  W. Catalona,et al.  Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. , 2004, The Journal of urology.

[78]  M. Kattan,et al.  PSA velocity and prostate cancer. , 2004, The New England journal of medicine.

[79]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[80]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[81]  J. Stanford,et al.  Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. , 2004, Journal of the National Cancer Institute.

[82]  W. Aronson,et al.  Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. , 2004, Urology.

[83]  J. Verweij,et al.  Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  B. Norlén,et al.  A systematic overview of radiation therapy effects in prostate cancer , 2004, Acta oncologica.

[85]  E. Barrett-Connor,et al.  Modifiable predictors of bone loss in older men: a prospective study. , 2004, American journal of preventive medicine.

[86]  D. L. Le Couteur,et al.  Aging Biology and Geriatric Clinical Pharmacology , 2004, Pharmacological Reviews.

[87]  Matthew R. Smith.  The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. , 2004, Oncology.

[88]  M. Menon,et al.  Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. , 2004, The Journal of urology.

[89]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  J. Droz,et al.  Geriatric assessment in elderly patients with prostate cancer. , 2004, Clinical prostate cancer.

[91]  H. Lepor,et al.  Continence following radical retropubic prostatectomy using self-reporting instruments. , 2004, The Journal of urology.

[92]  Bernhard Walter,et al.  High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. , 2004, Urology.

[93]  M. Kattan,et al.  Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  T. Beer,et al.  Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged ≥ 70 Years Compared with Patients Aged < 70 Years , 2003 .

[95]  C. Fallai,et al.  External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem. , 2003, Critical reviews in oncology/hematology.

[96]  G. Naglie,et al.  Continued undertreatment of older men with localized prostate cancer. , 2003, Urology.

[97]  L. Collette,et al.  Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group , 2003 .

[98]  Guy Vallancien,et al.  High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. , 2003, Journal of endourology.

[99]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[100]  J. Goodwin,et al.  Effect of Nurse Case Management on the Treatment of Older Women with Breast Cancer , 2003, Journal of the American Geriatrics Society.

[101]  G. Naglie,et al.  Do older men benefit from curative therapy of localized prostate cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  M. Kattan,et al.  Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. , 2003, Urology.

[103]  A. D'Amico,et al.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  P. Walsh.  Quality of life after radical prostatectomy or watchful waiting. , 2003, The Journal of urology.

[105]  J. Moul,et al.  Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. , 2003, International journal of radiation oncology, biology, physics.

[106]  M. Aapro,et al.  Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. , 2003, Critical reviews in oncology/hematology.

[107]  L. Collette,et al.  Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. , 2003, European urology.

[108]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[109]  U. P. S. T. Force,et al.  Screening for Prostate Cancer: Recommendation and Rationale , 2002, Annals of Internal Medicine.

[110]  A. Renshaw,et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Laurence R. Paquette,et al.  Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.

[112]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[113]  C. Abbou,et al.  Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. , 2002, European urology.

[114]  P. Walsh.  Variations in morbidity after radical prostatectomy. , 2002, The Journal of urology.

[115]  C. Reddy,et al.  Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[117]  Patrick C. Walsh,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[118]  Matthias Egger,et al.  Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. , 2002, JAMA.

[119]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[120]  M. Barry,et al.  Treatments for prostate cancer in older men: 1984-1997. , 2001, Urology.

[121]  J. Blasko,et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.

[122]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[123]  R. Parker,et al.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. , 2001, The Journal of clinical endocrinology and metabolism.

[124]  T Ostbye,et al.  A reevaluation of the duration of survival after the onset of dementia. , 2001, The New England journal of medicine.

[125]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[126]  C. Jepson,et al.  ADVANCING GERIATRIC NURSING PRACTICE; A Specialized Home Care Intervention Improves Survival Among Older Post‐Surgical Cancer Patients , 2000, Journal of the American Geriatrics Society.

[127]  S. Lichtman,et al.  Pharmacology of antineoplastic agents in older cancer patients. , 2000, Oncology.

[128]  M W Kattan,et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  M. Extermann,et al.  Management of cancer in the older person: a practical approach. , 2000, The oncologist.

[130]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[131]  M. Extermann,et al.  Measuring comorbidity in older cancer patients. , 2000, European journal of cancer.

[132]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[133]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[134]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[135]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[136]  P J Garry,et al.  The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. , 1999, Nutrition.

[137]  Kenneth Rockwood,et al.  A brief clinical instrument to classify frailty in elderly people , 1999, The Lancet.

[138]  R. Lerski,et al.  Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  G. Lyman,et al.  Comprehensive Geriatric Oncology , 1997 .

[140]  M. Extermann,et al.  Cancer chemotherapy in the older patient , 1997, Cancer.

[141]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[142]  B. Vellas,et al.  Mini Nutritional Assessment: a practical assessment tool for grading the nutritional state of elderly patients. , 1997 .

[143]  Y. Conwell,et al.  Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. , 1997, Archives of internal medicine.

[144]  S. Lichtman.  Physiological Aspects of Aging , 1995 .

[145]  M. Barry,et al.  Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. , 1995, Urology.

[146]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[147]  J. Oesterling,et al.  Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[149]  A. Hanlon,et al.  Patterns of radiation treatment of elderly patients with prostate cancer , 1994, Cancer.

[150]  L. Rubenstein,et al.  Comprehensive geriatric assessment: a meta-analysis of controlled trials , 1993, The Lancet.

[151]  Dale McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[152]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[153]  M. Egorin,et al.  Cancer pharmacology in the elderly. , 1993, Seminars in oncology.

[154]  Sati Mazumdar,et al.  Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale , 1992, Psychiatry Research.

[155]  F. Balis.  Pharmacokinetic Drug Interactions of Commonly Used Anticancer Drugs , 1986, Clinical pharmacokinetics.

[156]  M. Tinetti.  Performance‐Oriented Assessment of Mobility Problems in Elderly Patients , 1986, Journal of the American Geriatrics Society.

[157]  Heyssel Rm.  Academic medical center. , 1985, The New physician.

[158]  B. Brenner,et al.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. , 1982, The New England journal of medicine.

[159]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[160]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[161]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[162]  B. Linn,et al.  CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.

[163]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[164]  L. Lasagna,et al.  Newer techniques and some problems in cooperative group studies. , 1960, National Cancer Institute monograph.

[165]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[166]  J. Droz,et al.  Effects of comorbidity on screening and early diagnosis of cancer in elderly people. , 2009, The Lancet. Oncology.

[167]  P. Carroll,et al.  Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. , 2009, European urology.

[168]  A. Zarkar,et al.  Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. , 2008, Oncology reports.

[169]  C. Bokemeyer,et al.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. , 2007, European journal of cancer.

[170]  H. Wildiers,et al.  International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. , 2007, European journal of cancer.

[171]  K. Hunter,et al.  Conservative management for postprostatectomy urinary incontinence. , 2007, The Cochrane database of systematic reviews.

[172]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[173]  M. Duh,et al.  Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. , 2006, The Journal of urology.

[174]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2006 , 2006, CA: a cancer journal for clinicians.

[175]  T. Agnew.  Words of wisdom. , 2005, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[176]  W. Haley,et al.  A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. , 2004, Critical reviews in oncology/hematology.

[177]  T. Beer,et al.  Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. , 2003, Clinical prostate cancer.

[178]  A. Renshaw,et al.  Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma , 2003, Cancer.

[179]  M. Highley,et al.  Pharmacology of Anticancer Drugs in the Elderly Population , 2003, Clinical pharmacokinetics.

[180]  C. Glazener,et al.  Conservative management for post prostatectomy urinary incontinence. , 2001, The Cochrane database of systematic reviews.

[181]  A. Renshaw,et al.  Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  F. Marshall,et al.  Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.

[183]  S. Lichtman.  Physiological aspects of aging. Implications for the treatment of cancer. , 1995, Drugs & aging.

[184]  C. Mackenzie,et al.  Relating patient characteristics at the time of admission to outcomes of hospitalization. , 1991, Journal of clinical epidemiology.

[185]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[186]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.